Sanofi SA Receives “Neutral” Rating from Zacks (SNY)
Sanofi SA (NYSE:SNY)‘s stock had its “neutral” rating restated by Zacks in a research note issued to investors on Monday. They currently have a $56.00 target price on the stock. Zacks‘s price target would suggest a potential upside of 5.28% from the stock’s previous close.
Zacks’ analyst wrote, “Sanofi’s second quarter 2014 business earnings of $0.80 per American Depositary Share (ADS) was a penny above the Zacks Consensus Estimate. Second quarter net sales increased 0.9% on a reported basis and 6.4% at CER. The company raised its 2014 business earnings per share guidance following the strong performance in this quarter despite increasing competition in the U.S. The company expects business earnings to increase in the range of 6%-8% at CER. We are pleased with Sanofi’s deals and expect to see more activity on the deal/acquisition front. We are nevertheless disappointed with the string of pipeline setbacks at the company in the recent past despite some promising candidates. We maintain a Neutral recommendation on the stock. “
Separately, analysts at Mainfirst upgraded shares of Sanofi SA to an “outperform” rating in a research note on Monday, July 28th. Six research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Sanofi SA has an average rating of “Hold” and a consensus target price of $54.50.
Shares of Sanofi SA (NYSE:SNY) traded up 0.04% on Monday, hitting $53.21. 332,935 shares of the company’s stock traded hands. Sanofi SA has a one year low of $46.95 and a one year high of $54.64. The stock’s 50-day moving average is $52.60 and its 200-day moving average is $51.92. The company has a market cap of $139.9 billion and a P/E ratio of 25.60.
Sanofi SA (NYSE:SNY) last announced its earnings results on Thursday, July 31st. The company reported $0.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.79 by $0.07. On average, analysts predict that Sanofi SA will post $3.50 earnings per share for the current fiscal year.
Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.